المؤلفون: Cordón, Lourdes, Chorão, Pedro, Martín-Herreros, Beatriz, Montoro, Juan, Balaguer, Aitana, Guerreiro, Manuel, Villalba, Marta, Facal, Ana, Asensi, Pedro, Solves, Pilar, Gómez, Inés, Santiago, Marta, Lamas, Brais, Bataller, Ana, Granados, Pablo, Sempere, Amparo, Sanz, Guillermo F., Sanz, Miguel A., Sanz, Jaime

المصدر: Annals of Hematology; Jul2024, Vol. 103 Issue 7, p2475-2484, 10p

مستخلص: This study aimed to investigate the kinetics of immune recovery following umbilical cord blood transplantation (UCBT) in adults who received a myeloablative conditioning (MAC) regimen and antithymocyte globulin (ATG). While the immune recovery kinetics has been extensively studied in pediatric UCBT recipients, limited data exist for adults. We conducted a comprehensive analysis of 221 consecutive adult patients who underwent UCBT with MAC and ATG at a single institution. Our objective was to evaluate the influence of patient, disease, and transplant factors, along with acute graft-versus-host disease (aGVHD), on immune reconstitution and overall survival. Our findings confirm a delayed recovery of T cells, while B and NK cell reconstitution exhibited rapid progress, with NK cell counts reaching normal levels within 3 months post-transplantation and B cells within 6 months. Within CD3⁺ T cells, CD8⁺ T cells also experienced a delayed recovery (12 months), but to a lesser extent compared to CD4⁺ T cells (18 months). Delayed immune recovery of T-cell subsets was associated with the development of aGVHD grade II-IV, older age, CMV negativity, and a female donor. Patients with lymphoproliferative diseases showed slower NK cell recovery. Our study demonstrates that adult patients undergoing MAC with ATG and receiving a single unit UCBT for hematologic malignancies experienced rapid reconstitution of NK and B cells. However, T cell recovery, particularly CD4⁺ T cells, was significantly delayed. To enhance T cell recovery, it may be crucial to consider UCB units with higher cellularity and optimize ATG doses in conditioning. [ABSTRACT FROM AUTHOR]

: Copyright of Annals of Hematology is the property of Springer Nature and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)

المؤلفون: Chorão, Pedro, Henriques, Marta, Villalba, Marta, Montoro, Juan, Balaguer-Roselló, Aitana, González, Eva María, Gómez, María Dolores, Gómez, Inés, Solves, Pilar, Santiago, Marta, Asensi, Pedro, Lamas, Brais, Bataller, Ana, Granados, Pablo, Eiris, Juan, Martínez, David, Louro, Alberto, Rebollar, Paula, Perla, Aurora, Salavert, Miguel, de la Rubia, Javier, Sanz, Miguel Ángel, Sanz, Jaime

المصدر: Transplantation and Cellular Therapy; May 2024, Vol. 30 Issue: 5 p538.e1-538.e10, 48430p

مستخلص: • First CMV reactivations in HSCT with PTCy without letermovir prophylaxis occurred in 46% of patients.• The reactivation rate was 73% for CMV seropositive recipients and 49% for CMV-seropositive donors.• Risk factors for reactivation were CMV seropositivity, haploidentical HSCT, older patient, and grade II-IV acute GVHD.• Second and third CMV reactivations occurred in 13% and 4.4% of patients, independent of donor type.

المؤلفون: Sanz, Miguel Ángel, Montoro, Juan, Balaguer-Roselló, Aitana, Chorão, Pedro, Villalba, Marta, Gómez, Inés, Solves, Pilar, Santiago, Marta, Asensi, Pedro, Lamas, Brais, Bataller, Ana, Granados, Pablo, Eiris, Juan, Martinez, David, Lloret, Pilar, Louro, Alberto, Rebollar, Paula, Perla, Aurora, de la Rubia, Javier, Sanz, Jaime

المصدر: Bone Marrow Transplant ; ISSN:1476-5365

الوصف: This 45-year study (1978-2022) at a single institution evaluated HSCT outcomes and complications, emphasizing recent advances, with to provide insights into HSCT's evolving field and ongoing efforts to enhance patient outcomes. Involving 1707 patients, the study revealed an initial phase (1978-1987) with a limited activity that yielded modest outcomes, a nearly three-decade span (1988-2016) with a substantial increase in transplant activity, emphasizing umbilical cord blood transplantation (UCBT) for patients lacking a suitable matched sibling donor. In addition to a gradual increase in recipient age, significant improvement in outcomes emerged in the recent period (2017-2022), marked by UCBT replacement with haploidentical transplants, introduction of PTCY-based GVHD prophylaxis for all type of transplants, and increased use of conditioning regimens with thiotepa, busulfan, and fludarabine. In this period, reductions in GVHD, non-relapse mortality, and relapse rates significantly contributed to improved overall survival, event-free survival, and GVHD-free/relapse-free survival. The study identified specific factors, including GVHD prophylaxis and donor selection changes, associated with these positive trends. This four-decade study provides a unique perspective on allogeneic HSCT, showcasing the dynamic evolution of transplantation practices and their impact on outcomes, offering valuable insights for personalized treatment approaches and emphasizing continual innovation in this critical therapeutic modality.

العلاقة: https://doi.org/10.1038/s41409-024-02319-xTest; https://pubmed.ncbi.nlm.nih.gov/38918495Test

الإتاحة: https://doi.org/10.1038/s41409-024-02319-xTest
https://pubmed.ncbi.nlm.nih.gov/38918495Test

المؤلفون: Vilorio-Marqués, Laura, Castañón Fernández, Christelle, Mora, Elvira, Gutiérrez, Lorena, Rey Bua, Beatriz, Jiménez Lorenzo, Maria José, Díaz-Beyá, Marina, Vara Pampliega, Miriam, Molero, Antonieta, Sánchez-García, Joaquín, Calabuig, Marisa, Cedena, María Teresa, Chen-Liang, Tzu, Díaz Santa, Johana Alejandra, Padilla, Irene, Hernández, Francisca, Díez, Rosana, Asensi, Pedro, Xicoy, Blanca, Sanz, Guillermo, Valcárcel, David, Diez-Campelo, María, Bernal, Teresa, Institut Germans Trias i Pujol. Institut de Recerca contra la Leucèmia Josep Carreras, Universitat Autònoma de Barcelona

الوصف: The authors declared the following potential conflict of interest with respect to the research, authorship, and/or publication of this article: T.B. has received support for attending meetings and/or travel from Jazz Pharmaceutical, honoraria from Jazz Pharmaceutical, BMS, and Pfizer. D.V. has received honoraria from Celgene/BMS, Amgen, Novartis, Jazz Pharmaceuticals, and Pfizer and support for attending meetings and/or travel from Amgen, BMS/Celgene, and Jazz. M.D.-C. reports honoraria and membership on entity's Board of directors or advisory committees from Novartis, BMS, and Takeda. Dr G.S. has received personal fees from AbbVie, Amgen, and Astellas and has received research funding from Celgene/BMS Janssen-Cilag, Novartis, Roche, and Takeda. ; Background: The consequences of infectious toxicity of hypomethylating agents (HMAs) on overall survival (OS) of patients diagnosed with high-risk myeloid neoplasms have not been thoroughly investigated. Objectives: We aimed to evaluate whether infectious events (IEs) negatively influenced the results of HMA treatment in a real-world setting. Design: Observational study. Methods: We obtained data from 412 non-selected consecutive patients from 23 Spanish hospitals who were diagnosed with high-risk myelodysplastic syndrome, chronic myelomonocytic leukemia, or acute myeloid leukemia and were treated with HMA. HMAs received after chemotherapy or stem cell transplant were excluded. All IEs were recorded. Outcomes included OS, modifications to the pre-planned treatment, incidence and characteristics of IEs, hospitalization, red blood cell transfusions, and factors associated with infection. Results: The rate of infection was 1.2 per patient/year. Next-cycle delay (p = 0.001) and hospitalizations (p = 0.001) were significantly influenced by IEs. Transfusion requirements during each cycle were significantly higher after infection compared with cycles without infection (coefficient = 1.55 [95% confidence interval (CI) = 1.26-1.84], p < 0.001). The median number of cycles ...

وصف الملف: application/pdf

العلاقة: Therapeutic Advances in Hematology; Vol. 13 (2022); https://ddd.uab.cat/record/270615Test; urn:10.1177/20406207221127547; urn:oai:ddd.uab.cat:270615; urn:scopus_id:85139196008; urn:pmid:36199837; urn:pmc-uid:9527993; urn:pmcid:PMC9527993; urn:oai:pubmedcentral.nih.gov:9527993; urn:oai:egreta.uab.cat:publications/c9c818a1-2c0b-4efa-8801-4f13832b23a4

الإتاحة: https://ddd.uab.cat/record/270615Test

المؤلفون: Vilorio-Marqués, Laura, Castañón Fernández, Christelle, Mora, Elvira, Gutiérrez, Lorena, Rey Bua, Beatriz, Jiménez Lorenzo, Maria José, Díaz Beya, Marina, Vara Pampliega, Miriam, Molero, Antonieta, Sánchez-García, Joaquín, Calabuig, Marisa, Cedena, Maria Teresa, Chen-Liang, Tzu, Díaz Santa, Johana Alejandra, Padilla, Irene, Hernández, Francisca, Díez, Rosana, Asensi, Pedro, Xicoy, Blanca, Sanz, Guillermo, Valcárcel, David, Diez-Campelo, María, Bernal, Teresa

المصدر: Therapeutic Advances in Hematology ; volume 13, page 204062072211275 ; ISSN 2040-6207 2040-6215

مصطلحات موضوعية: Hematology

الوصف: Background: The consequences of infectious toxicity of hypomethylating agents (HMAs) on overall survival (OS) of patients diagnosed with high-risk myeloid neoplasms have not been thoroughly investigated. Objectives: We aimed to evaluate whether infectious events (IEs) negatively influenced the results of HMA treatment in a real-world setting. Design: Observational study. Methods: We obtained data from 412 non-selected consecutive patients from 23 Spanish hospitals who were diagnosed with high-risk myelodysplastic syndrome, chronic myelomonocytic leukemia, or acute myeloid leukemia and were treated with HMA. HMAs received after chemotherapy or stem cell transplant were excluded. All IEs were recorded. Outcomes included OS, modifications to the pre-planned treatment, incidence and characteristics of IEs, hospitalization, red blood cell transfusions, and factors associated with infection. Results: The rate of infection was 1.2 per patient/year. Next-cycle delay ( p = 0.001) and hospitalizations ( p = 0.001) were significantly influenced by IEs. Transfusion requirements during each cycle were significantly higher after infection compared with cycles without infection (coefficient = 1.55 [95% confidence interval (CI) = 1.26–1.84], p < 0.001). The median number of cycles was lower in patients experiencing any infection during the first four cycles (5 [3–8] versu 8 [5–16], p < 0.001). In the multivariable analysis, factors associated with lower OS were having any infection during the first four cycles (hazard ratio (HR) = 1.43 [95% CI = 1.09–1.88], p = 0.01), bone marrow blasts ⩾30% (HR = 2.13 [95% CI = 1.14–3.96], p = 0.01), adverse cytogenetics (HR = 1.70 [95% CI = 1.30–2.24], p < 0.001), and platelet count <50 × 10 9 /l (HR = 1.69 [95% CI = 1.3–2.2], p < 0.001). BM blasts >20% (HR = 1.57 [95% CI = 1.19–2.01], p < 0.001) and adverse cytogenetics (HR = 1.7 [95% CI = 1.35–2.14], p < 0.001) were associated with infection, whereas hemoglobin >9 g/dl (HR = 0.65 [95% CI = 0.51–0.82], p < ...

الإتاحة: https://doi.org/10.1177/20406207221127547Test

المؤلفون: Boluda, Blanca, Solana-Altabella, Antonio, Cano, Isabel, Martínez-Cuadrón, David, Acuña-Cruz, Evelyn, Torres-Miñana, Laura, Rodríguez-Veiga, Rebeca, Navarro-Vicente, Irene, Martínez-Campuzano, David, García-Ruiz, Raquel, Lloret, Pilar, Asensi, Pedro, Osa-Sáez, Ana, Aguero, Jaume, Rodríguez-Serrano, María, Buendía-Fuentes, Francisco, Megías-Vericat, Juan Eduardo, Martín-Herreros, Beatriz, Barragán, Eva, Sargas, Claudia

المصدر: Cancers; Apr2023, Vol. 15 Issue 8, p2267, 23p

مصطلحات موضوعية: CARDIOTOXICITY, DISEASE incidence, DESCRIPTIVE statistics, RESEARCH funding, OVERALL survival, DISEASE management, ADULTS

مستخلص: Simple Summary: The incidence of cardiac morbimortality in acute myeloid leukemia (AML) is not well known. We aim to estimate the cumulative incidence (CI) of cardiac events in AML patients and to identify risk factors for their occurrence. We observed a high incidence of cardiac events (58.5%) among 525 treated patients, coupled with significant mortality due to cardiotoxicity (3.6%). The presence of relevant cardiac antecedents was the main risk factor for developing fatal cardiac events (hazard ratio (HR) = 1.9). Age ≥ 65 (HR = 2.2), relevant cardiac antecedents (HR = 1.4), and non-intensive chemotherapy (HR = 1.8) were associated with non-fatal cardiac events. We observed that, among 285 intensive therapy patients, median overall survival was decreased in those experiencing grade 3–4 cardiac events (p < 0.001). We identified prognostic factors that increase the risk of cardiac events, which may be useful in selecting high-risk patients for stringent cardiac monitoring and management. The incidence of cardiac morbimortality in acute myeloid leukemia (AML) is not well known. We aim to estimate the cumulative incidence (CI) of cardiac events in AML patients and to identify risk factors for their occurrence. Among 571 newly diagnosed AML patients, 26 (4.6%) developed fatal cardiac events, and among 525 treated patients, 19 (3.6%) experienced fatal cardiac events (CI: 2% at 6 months; 6.7% at 9 years). Prior heart disease was associated with the development of fatal cardiac events (hazard ratio (HR) = 6.9). The CI of non-fatal cardiac events was 43.7% at 6 months and 56.9% at 9 years. Age ≥ 65 (HR = 2.2), relevant cardiac antecedents (HR = 1.4), and non-intensive chemotherapy (HR = 1.8) were associated with non-fatal cardiac events. The 9-year CI of grade 1–2 QTcF prolongation was 11.2%, grade 3 was 2.7%, and no patient had grade 4–5 events. The 9-year CI of grade 1–2 cardiac failure was 1.3%, grade 3–4 was 15%, and grade 5 was 2.1%; of grade 1–2, arrhythmia was 1.9%, grade 3–4 was 9.1%, and grade 5 was 1%. Among 285 intensive therapy patients, median overall survival decreased in those experiencing grade 3–4 cardiac events (p < 0.001). We observed a high incidence of cardiac toxicity associated with significant mortality in AML. [ABSTRACT FROM AUTHOR]

: Copyright of Cancers is the property of MDPI and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)

المؤلفون: Vilorio-Marqués, Laura, Castañón Fernández, Christelle, Mora, Elvira, Gutiérrez, Lorena, Rey Bua, Beatriz, Jiménez Lorenzo, Maria José, Díaz Beya, Marina, Vara Pampliega, Miriam, Molero, Antonieta, Sánchez-García, Joaquín, Calabuig, Marisa, Cedena, Maria Teresa, Chen-Liang, Tzu, Díaz Santa, Johana Alejandra, Padilla, Irene, Hernández, Francisca, Díez, Rosana, Asensi, Pedro, Xicoy, Blanca, Sanz, Guillermo, Valcárcel, David, Diez-Campelo, María, Bernal, Teresa

مصطلحات موضوعية: FOS: Clinical medicine, Cardiology, 111599 Pharmacology and Pharmaceutical Sciences not elsewhere classified, 111299 Oncology and Carcinogenesis not elsewhere classified

الوصف: Supplemental material, sj-docx-1-tah-10.1177_20406207221127547 for Relevance of infections on the outcomes of patients with myelodysplastic syndromes, chronic myelomonocytic leukemia, and acute myeloid leukemia treated with hypomethylating agents: a cohort study from the GESMD by Laura Vilorio-Marqués, Christelle Castañón Fernández, Elvira Mora, Lorena Gutiérrez, Beatriz Rey Bua, Maria José Jiménez Lorenzo, Marina Díaz Beya, Miriam Vara Pampliega, Antonieta Molero, Joaquín Sánchez-García, Marisa Calabuig, Maria Teresa Cedena, Tzu Chen-Liang, Johana Alejandra Díaz Santa, Irene Padilla, Francisca Hernández, Rosana Díez, Pedro Asensi, Blanca Xicoy, Guillermo Sanz, David Valcárcel, María Diez-Campelo and Teresa Bernal in Therapeutic Advances in Hematology

الوصول الحر: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::052aeab7f37b467c340923336ec6b522Test

المؤلفون: Ibáñez, Mariam, Such, Esperanza, Liquori, Alessandro, Avestisyan, Gayane, Andreu, Rafael, Vicente, Ana, Macián, María José, Melendez, Mari Carmen, Morote-Faubel, Mireya, Asensi, Pedro, Lloret, María Pilar, Jarque, Isidro, Picón, Isabel, Pacios, Alejandro, Donato, Eva, Mas-Ochoa, Carmen, Alonso, Carmen, Cañigral, Carolina, Sempere, Amparo, Romero, Samuel

المصدر: Diagnostics (2075-4418); Apr2022, Vol. 12 Issue 4, p953-953, 10p

مصطلحات موضوعية: CHRONIC lymphocytic leukemia, DNA copy number variations, SOMATIC mutation, CHRONIC leukemia, GENETIC variation, NUCLEOTIDE sequencing, TREATMENT failure

مستخلص: According to current guidelines, in chronic lymphocytic leukemia (CLL), only the TP53 molecular status must be evaluated prior to every treatment's initiation. However, additional heterogeneous genetic events are known to confer a proliferative advantage to the tumor clone and are associated with progression and treatment failure in CLL patients. Here, we describe the implementation of a comprehensive targeted sequencing solution that is suitable for routine clinical practice and allows for the detection of the most common somatic single-nucleotide and copy number variants in genes relevant to CLL. We demonstrate that this cost-effective strategy achieves variant detection with high accuracy, specificity, and sensitivity. Furthermore, we identify somatic variants and copy number variations in genes with prognostic and/or predictive value, according to the most recent literature, and the tool provides evidence about subclonal events. This next-generation sequencing (NGS) capture-based target assay is an improvement on current approaches in defining molecular prognostic and/or predictive variables in CLL patients. [ABSTRACT FROM AUTHOR]

: Copyright of Diagnostics (2075-4418) is the property of MDPI and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)

المؤلفون: Escamilla Gomez, Virginia, García Gutiérrez, Valentín, Astibia Mahillo, Beatriz, Alcalde, Patricia, López Corral, Lucía, Acera Gómez, Marina, Torres, Melissa, Borrego Borrego, Asunción, González Pinedo, Leslie, Zudaire, Maite, González Vicent, Marta, Benzaquén, Ana, Izquierdo Garcia, Isabel, Asensi, Pedro, Montoro Gómez, Juan, Orti Pascual, Guillermo, Valcárcel, David, Benitez Carabante, Maria Isabel, Díaz de Heredia Rubio, Cristina, Cañamero Giro, Eloi, Ferrà, Christelle, García-Cadenas, Irene, Redondo, Sara, Sisinni, Luisa, Perez, Antonio, Mussetti, Alberto, García, Lucía, Palomo Moraleda, María Del Pilar, González Sierra, Pedro Antonio, Jurado Chacón, Manuel, Perez-Simon, Jose A.

المصدر: Blood; November 2022, Vol. 140 Issue: 1, Number 1 Supplement 1 p7754-7756, 3p